Global Cluster Headache Drug Market
Global Cluster Headache Drug Market

Cluster Headache Drug Comprehensive Study by Type (Episodic, Chronic), Drug (Fast-Acting Drugs, Long-Term Drugs, Short-Term Drugs), Mechanism of Action (Corticosteroids, Ergot alkaloids (Dihydroergotamine, Ergotamine), Local Anesthetics, Calcium Channel Blockers, Triptans, Lithium Carbonate, Anti-Seizures), Treatment (Medication, Surgery), Route of Administration (Oral, Topical, Intravenous, Others), Diagnosis (Neurological Examination, MRI, CT Scan), End User (Hospitals, Homecare, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2026

Cluster Headache Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 226 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Cluster Headache Drug Market Overview:
Cluster headache, also known as Horton's syndrome, is characterised by a series of brief but intense headaches on one side of the head that occur every day for weeks or months. Cluster headaches arise when a person has a series of attacks that range from weeks to months and are followed by long periods of relief. Cluster headaches develop at the same time every year due to their cyclical nature.

Growth Drivers
  • Increasing prevalence of cluster headaches and migraine
  • Increased television viewing and computer usage
  • Growing geriatric population

Roadblocks
  • Lack of awareness amongst people and healthcare providers about cluster headaches
  • Unfavorable health care policies

Opportunities
  • Application of latest technologies in the health care industry
  • Growth potential in developing countries

Challenges
  • Increasing measure by government to lessen healthcare expenditure


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Pfizer Inc (United States), AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), TrioxBio Inc (Israel), Aurobindo Pharma (India), Endo Pharmaceuticals Inc (Ireland) and Chengdu Tiantaishan pharmaceutical Co.,Ltd (China). Additionally, following companies can also be profiled that are part of our coverage like WOCKHARDT (India) and Shanghai Soho Yiming Pharmaceutical Co., Ltd (China). Analyst at AMA Research see United States Players to retain maximum share of Global Cluster Headache Drug market by 2026. Considering Market by Drug, the sub-segment i.e. Fast-Acting Drugs will boost the Cluster Headache Drug market. Considering Market by Mechanism of Action, the sub-segment i.e. Corticosteroids will boost the Cluster Headache Drug market. Considering Market by Treatment, the sub-segment i.e. Medication will boost the Cluster Headache Drug market. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Cluster Headache Drug market. Considering Market by Diagnosis, the sub-segment i.e. Neurological Examination will boost the Cluster Headache Drug market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Cluster Headache Drug market.

Latest Market Insights:
In April 2017, electroCore, Inc received the US FDA approval for gammaCore device, a non-invasive vagus nerve stimulator aimed to treat pain associated with episodic cluster headache in adult patients. Gammacore the first and only FDA-approved device for the prevention of cluster headache. It is a safe and effective treatment when compared to other treatments

In June 2019, Eli Lilly and Company received the US FDA approval for Emgality (Galcanezumab). This drug became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks. It belongs to a new class of drugs called CGRP inhibitors that are used to prevent migraines or reduce their frequency

What Can be Explored with the Cluster Headache Drug Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Cluster Headache Drug Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Cluster Headache Drug
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cluster Headache Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cluster Headache Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Cluster Headaches Drug, Government Regulatory and Research Organizations and End-Use Industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Cluster Headache Drug Market?
The Cluster Headache Drug market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Cluster Headache Drug Market?
Top performing companies in the Global Cluster Headache Drug market are F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Pfizer Inc (United States), AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), TrioxBio Inc (Israel), Aurobindo Pharma (India), Endo Pharmaceuticals Inc (Ireland) and Chengdu Tiantaishan pharmaceutical Co.,Ltd (China), to name a few.

3. What trending factors would impact Cluster Headache Drug Market growth most?
"Increase in the rate of R&D initiatives" is seen as one of major influencing trends for Cluster Headache Drug Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • Episodic
  • Chronic
By Drug
  • Fast-Acting Drugs
  • Long-Term Drugs
  • Short-Term Drugs

By Mechanism of Action
  • Corticosteroids
  • Ergot alkaloids (Dihydroergotamine, Ergotamine)
  • Local Anesthetics
  • Calcium Channel Blockers
  • Triptans
  • Lithium Carbonate
  • Anti-Seizures

By Treatment
  • Medication
  • Surgery

By Route of Administration
  • Oral
  • Topical
  • Intravenous
  • Others

By Diagnosis
  • Neurological Examination
  • MRI
  • CT Scan

By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Chile
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Thailand
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Sweden
    • Belgium
    • Poland
    • Norway
    • Austria
    • Russia
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of cluster headaches and migraine
      • 3.2.2. Increased television viewing and computer usage
      • 3.2.3. Growing geriatric population
    • 3.3. Market Challenges
      • 3.3.1. Increasing measure by government to lessen healthcare expenditure
    • 3.4. Market Trends
      • 3.4.1. Increase in the rate of R&D initiatives
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cluster Headache Drug, by Type, Drug, Mechanism of Action, Treatment, Route of Administration, Diagnosis, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cluster Headache Drug (Value)
      • 5.2.1. Global Cluster Headache Drug by: Type (Value)
        • 5.2.1.1. Episodic
        • 5.2.1.2. Chronic
      • 5.2.2. Global Cluster Headache Drug by: Drug (Value)
        • 5.2.2.1. Fast-Acting Drugs
        • 5.2.2.2. Long-Term Drugs
        • 5.2.2.3. Short-Term Drugs
      • 5.2.3. Global Cluster Headache Drug by: Mechanism of Action (Value)
        • 5.2.3.1. Corticosteroids
        • 5.2.3.2. Ergot alkaloids (Dihydroergotamine, Ergotamine)
        • 5.2.3.3. Local Anesthetics
        • 5.2.3.4. Calcium Channel Blockers
        • 5.2.3.5. Triptans
        • 5.2.3.6. Lithium Carbonate
        • 5.2.3.7. Anti-Seizures
      • 5.2.4. Global Cluster Headache Drug by: Treatment (Value)
        • 5.2.4.1. Medication
        • 5.2.4.2. Surgery
      • 5.2.5. Global Cluster Headache Drug by: Route of Administration (Value)
        • 5.2.5.1. Oral
        • 5.2.5.2. Topical
        • 5.2.5.3. Intravenous
        • 5.2.5.4. Others
      • 5.2.6. Global Cluster Headache Drug by: Diagnosis (Value)
        • 5.2.6.1. Neurological Examination
        • 5.2.6.2. MRI
        • 5.2.6.3. CT Scan
      • 5.2.7. Global Cluster Headache Drug by: End User (Value)
        • 5.2.7.1. Hospitals
        • 5.2.7.2. Homecare
        • 5.2.7.3. Specialty Clinics
        • 5.2.7.4. Others
      • 5.2.8. Global Cluster Headache Drug Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Chile
          • 5.2.8.1.4. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Singapore
          • 5.2.8.2.6. Malaysia
          • 5.2.8.2.7. Thailand
          • 5.2.8.2.8. Australia
          • 5.2.8.2.9. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Spain
          • 5.2.8.3.7. Sweden
          • 5.2.8.3.8. Belgium
          • 5.2.8.3.9. Poland
          • 5.2.8.3.10. Norway
          • 5.2.8.3.11. Austria
          • 5.2.8.3.12. Russia
          • 5.2.8.3.13. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
  • 6. Cluster Headache Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sun Pharmaceutical Industries Ltd (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. TrioxBio Inc (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aurobindo Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Endo Pharmaceuticals Inc (Ireland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Chengdu Tiantaishan pharmaceutical Co.,Ltd (China)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Cluster Headache Drug Sale, by Type, Drug, Mechanism of Action, Treatment, Route of Administration, Diagnosis, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cluster Headache Drug (Value)
      • 7.2.1. Global Cluster Headache Drug by: Type (Value)
        • 7.2.1.1. Episodic
        • 7.2.1.2. Chronic
      • 7.2.2. Global Cluster Headache Drug by: Drug (Value)
        • 7.2.2.1. Fast-Acting Drugs
        • 7.2.2.2. Long-Term Drugs
        • 7.2.2.3. Short-Term Drugs
      • 7.2.3. Global Cluster Headache Drug by: Mechanism of Action (Value)
        • 7.2.3.1. Corticosteroids
        • 7.2.3.2. Ergot alkaloids (Dihydroergotamine, Ergotamine)
        • 7.2.3.3. Local Anesthetics
        • 7.2.3.4. Calcium Channel Blockers
        • 7.2.3.5. Triptans
        • 7.2.3.6. Lithium Carbonate
        • 7.2.3.7. Anti-Seizures
      • 7.2.4. Global Cluster Headache Drug by: Treatment (Value)
        • 7.2.4.1. Medication
        • 7.2.4.2. Surgery
      • 7.2.5. Global Cluster Headache Drug by: Route of Administration (Value)
        • 7.2.5.1. Oral
        • 7.2.5.2. Topical
        • 7.2.5.3. Intravenous
        • 7.2.5.4. Others
      • 7.2.6. Global Cluster Headache Drug by: Diagnosis (Value)
        • 7.2.6.1. Neurological Examination
        • 7.2.6.2. MRI
        • 7.2.6.3. CT Scan
      • 7.2.7. Global Cluster Headache Drug by: End User (Value)
        • 7.2.7.1. Hospitals
        • 7.2.7.2. Homecare
        • 7.2.7.3. Specialty Clinics
        • 7.2.7.4. Others
      • 7.2.8. Global Cluster Headache Drug Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Chile
          • 7.2.8.1.4. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Singapore
          • 7.2.8.2.6. Malaysia
          • 7.2.8.2.7. Thailand
          • 7.2.8.2.8. Australia
          • 7.2.8.2.9. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Spain
          • 7.2.8.3.7. Sweden
          • 7.2.8.3.8. Belgium
          • 7.2.8.3.9. Poland
          • 7.2.8.3.10. Norway
          • 7.2.8.3.11. Austria
          • 7.2.8.3.12. Russia
          • 7.2.8.3.13. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cluster Headache Drug: by Type(USD Million)
  • Table 2. Cluster Headache Drug Episodic , by Region USD Million (2015-2020)
  • Table 3. Cluster Headache Drug Chronic , by Region USD Million (2015-2020)
  • Table 4. Cluster Headache Drug: by Drug(USD Million)
  • Table 5. Cluster Headache Drug Fast-Acting Drugs , by Region USD Million (2015-2020)
  • Table 6. Cluster Headache Drug Long-Term Drugs , by Region USD Million (2015-2020)
  • Table 7. Cluster Headache Drug Short-Term Drugs , by Region USD Million (2015-2020)
  • Table 8. Cluster Headache Drug: by Mechanism of Action(USD Million)
  • Table 9. Cluster Headache Drug Corticosteroids , by Region USD Million (2015-2020)
  • Table 10. Cluster Headache Drug Ergot alkaloids (Dihydroergotamine, Ergotamine) , by Region USD Million (2015-2020)
  • Table 11. Cluster Headache Drug Local Anesthetics , by Region USD Million (2015-2020)
  • Table 12. Cluster Headache Drug Calcium Channel Blockers , by Region USD Million (2015-2020)
  • Table 13. Cluster Headache Drug Triptans , by Region USD Million (2015-2020)
  • Table 14. Cluster Headache Drug Lithium Carbonate , by Region USD Million (2015-2020)
  • Table 15. Cluster Headache Drug Anti-Seizures , by Region USD Million (2015-2020)
  • Table 16. Cluster Headache Drug: by Treatment(USD Million)
  • Table 17. Cluster Headache Drug Medication , by Region USD Million (2015-2020)
  • Table 18. Cluster Headache Drug Surgery , by Region USD Million (2015-2020)
  • Table 19. Cluster Headache Drug: by Route of Administration(USD Million)
  • Table 20. Cluster Headache Drug Oral , by Region USD Million (2015-2020)
  • Table 21. Cluster Headache Drug Topical , by Region USD Million (2015-2020)
  • Table 22. Cluster Headache Drug Intravenous , by Region USD Million (2015-2020)
  • Table 23. Cluster Headache Drug Others , by Region USD Million (2015-2020)
  • Table 24. Cluster Headache Drug: by Diagnosis(USD Million)
  • Table 25. Cluster Headache Drug Neurological Examination , by Region USD Million (2015-2020)
  • Table 26. Cluster Headache Drug MRI , by Region USD Million (2015-2020)
  • Table 27. Cluster Headache Drug CT Scan , by Region USD Million (2015-2020)
  • Table 28. Cluster Headache Drug: by End User(USD Million)
  • Table 29. Cluster Headache Drug Hospitals , by Region USD Million (2015-2020)
  • Table 30. Cluster Headache Drug Homecare , by Region USD Million (2015-2020)
  • Table 31. Cluster Headache Drug Specialty Clinics , by Region USD Million (2015-2020)
  • Table 32. Cluster Headache Drug Others , by Region USD Million (2015-2020)
  • Table 33. South America Cluster Headache Drug, by Country USD Million (2015-2020)
  • Table 34. South America Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 35. South America Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 36. South America Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 37. South America Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 38. South America Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 39. South America Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 40. South America Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 41. Brazil Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 42. Brazil Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 43. Brazil Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 44. Brazil Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 45. Brazil Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 46. Brazil Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 47. Brazil Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 48. Argentina Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 49. Argentina Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 50. Argentina Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 51. Argentina Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 52. Argentina Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 53. Argentina Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 54. Argentina Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 55. Chile Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 56. Chile Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 57. Chile Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 58. Chile Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 59. Chile Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 60. Chile Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 61. Chile Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 62. Rest of South America Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 63. Rest of South America Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 64. Rest of South America Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 65. Rest of South America Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 66. Rest of South America Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 67. Rest of South America Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 68. Rest of South America Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 69. Asia Pacific Cluster Headache Drug, by Country USD Million (2015-2020)
  • Table 70. Asia Pacific Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 71. Asia Pacific Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 72. Asia Pacific Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 73. Asia Pacific Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 74. Asia Pacific Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 75. Asia Pacific Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 76. Asia Pacific Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 77. China Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 78. China Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 79. China Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 80. China Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 81. China Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 82. China Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 83. China Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 84. Japan Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 85. Japan Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 86. Japan Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 87. Japan Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 88. Japan Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 89. Japan Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 90. Japan Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 91. India Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 92. India Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 93. India Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 94. India Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 95. India Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 96. India Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 97. India Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 98. South Korea Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 99. South Korea Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 100. South Korea Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 101. South Korea Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 102. South Korea Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 103. South Korea Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 104. South Korea Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 105. Singapore Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 106. Singapore Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 107. Singapore Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 108. Singapore Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 109. Singapore Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 110. Singapore Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 111. Singapore Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 112. Malaysia Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 113. Malaysia Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 114. Malaysia Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 115. Malaysia Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 116. Malaysia Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 117. Malaysia Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 118. Malaysia Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 119. Thailand Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 120. Thailand Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 121. Thailand Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 122. Thailand Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 123. Thailand Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 124. Thailand Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 125. Thailand Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 126. Australia Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 127. Australia Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 128. Australia Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 129. Australia Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 130. Australia Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 131. Australia Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 132. Australia Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 133. Rest of Asia-Pacific Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 134. Rest of Asia-Pacific Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 135. Rest of Asia-Pacific Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 136. Rest of Asia-Pacific Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 137. Rest of Asia-Pacific Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 138. Rest of Asia-Pacific Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 139. Rest of Asia-Pacific Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 140. Europe Cluster Headache Drug, by Country USD Million (2015-2020)
  • Table 141. Europe Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 142. Europe Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 143. Europe Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 144. Europe Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 145. Europe Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 146. Europe Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 147. Europe Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 148. Germany Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 149. Germany Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 150. Germany Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 151. Germany Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 152. Germany Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 153. Germany Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 154. Germany Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 155. France Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 156. France Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 157. France Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 158. France Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 159. France Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 160. France Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 161. France Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 162. Italy Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 163. Italy Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 164. Italy Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 165. Italy Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 166. Italy Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 167. Italy Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 168. Italy Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 169. United Kingdom Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 170. United Kingdom Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 171. United Kingdom Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 172. United Kingdom Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 173. United Kingdom Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 174. United Kingdom Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 175. United Kingdom Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 176. Netherlands Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 177. Netherlands Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 178. Netherlands Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 179. Netherlands Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 180. Netherlands Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 181. Netherlands Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 182. Netherlands Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 183. Spain Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 184. Spain Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 185. Spain Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 186. Spain Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 187. Spain Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 188. Spain Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 189. Spain Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 190. Sweden Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 191. Sweden Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 192. Sweden Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 193. Sweden Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 194. Sweden Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 195. Sweden Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 196. Sweden Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 197. Belgium Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 198. Belgium Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 199. Belgium Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 200. Belgium Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 201. Belgium Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 202. Belgium Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 203. Belgium Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 204. Poland Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 205. Poland Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 206. Poland Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 207. Poland Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 208. Poland Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 209. Poland Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 210. Poland Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 211. Norway Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 212. Norway Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 213. Norway Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 214. Norway Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 215. Norway Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 216. Norway Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 217. Norway Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 218. Austria Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 219. Austria Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 220. Austria Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 221. Austria Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 222. Austria Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 223. Austria Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 224. Austria Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 225. Russia Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 226. Russia Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 227. Russia Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 228. Russia Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 229. Russia Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 230. Russia Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 231. Russia Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 232. Rest of Europe Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 233. Rest of Europe Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 234. Rest of Europe Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 235. Rest of Europe Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 236. Rest of Europe Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 237. Rest of Europe Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 238. Rest of Europe Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 239. MEA Cluster Headache Drug, by Country USD Million (2015-2020)
  • Table 240. MEA Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 241. MEA Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 242. MEA Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 243. MEA Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 244. MEA Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 245. MEA Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 246. MEA Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 247. Middle East Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 248. Middle East Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 249. Middle East Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 250. Middle East Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 251. Middle East Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 252. Middle East Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 253. Middle East Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 254. Africa Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 255. Africa Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 256. Africa Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 257. Africa Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 258. Africa Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 259. Africa Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 260. Africa Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 261. North America Cluster Headache Drug, by Country USD Million (2015-2020)
  • Table 262. North America Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 263. North America Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 264. North America Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 265. North America Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 266. North America Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 267. North America Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 268. North America Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 269. United States Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 270. United States Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 271. United States Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 272. United States Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 273. United States Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 274. United States Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 275. United States Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 276. Canada Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 277. Canada Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 278. Canada Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 279. Canada Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 280. Canada Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 281. Canada Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 282. Canada Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 283. Mexico Cluster Headache Drug, by Type USD Million (2015-2020)
  • Table 284. Mexico Cluster Headache Drug, by Drug USD Million (2015-2020)
  • Table 285. Mexico Cluster Headache Drug, by Mechanism of Action USD Million (2015-2020)
  • Table 286. Mexico Cluster Headache Drug, by Treatment USD Million (2015-2020)
  • Table 287. Mexico Cluster Headache Drug, by Route of Administration USD Million (2015-2020)
  • Table 288. Mexico Cluster Headache Drug, by Diagnosis USD Million (2015-2020)
  • Table 289. Mexico Cluster Headache Drug, by End User USD Million (2015-2020)
  • Table 290. Company Basic Information, Sales Area and Its Competitors
  • Table 291. Company Basic Information, Sales Area and Its Competitors
  • Table 292. Company Basic Information, Sales Area and Its Competitors
  • Table 293. Company Basic Information, Sales Area and Its Competitors
  • Table 294. Company Basic Information, Sales Area and Its Competitors
  • Table 295. Company Basic Information, Sales Area and Its Competitors
  • Table 296. Company Basic Information, Sales Area and Its Competitors
  • Table 297. Company Basic Information, Sales Area and Its Competitors
  • Table 298. Company Basic Information, Sales Area and Its Competitors
  • Table 299. Company Basic Information, Sales Area and Its Competitors
  • Table 300. Company Basic Information, Sales Area and Its Competitors
  • Table 301. Company Basic Information, Sales Area and Its Competitors
  • Table 302. Cluster Headache Drug: by Type(USD Million)
  • Table 303. Cluster Headache Drug Episodic , by Region USD Million (2021-2026)
  • Table 304. Cluster Headache Drug Chronic , by Region USD Million (2021-2026)
  • Table 305. Cluster Headache Drug: by Drug(USD Million)
  • Table 306. Cluster Headache Drug Fast-Acting Drugs , by Region USD Million (2021-2026)
  • Table 307. Cluster Headache Drug Long-Term Drugs , by Region USD Million (2021-2026)
  • Table 308. Cluster Headache Drug Short-Term Drugs , by Region USD Million (2021-2026)
  • Table 309. Cluster Headache Drug: by Mechanism of Action(USD Million)
  • Table 310. Cluster Headache Drug Corticosteroids , by Region USD Million (2021-2026)
  • Table 311. Cluster Headache Drug Ergot alkaloids (Dihydroergotamine, Ergotamine) , by Region USD Million (2021-2026)
  • Table 312. Cluster Headache Drug Local Anesthetics , by Region USD Million (2021-2026)
  • Table 313. Cluster Headache Drug Calcium Channel Blockers , by Region USD Million (2021-2026)
  • Table 314. Cluster Headache Drug Triptans , by Region USD Million (2021-2026)
  • Table 315. Cluster Headache Drug Lithium Carbonate , by Region USD Million (2021-2026)
  • Table 316. Cluster Headache Drug Anti-Seizures , by Region USD Million (2021-2026)
  • Table 317. Cluster Headache Drug: by Treatment(USD Million)
  • Table 318. Cluster Headache Drug Medication , by Region USD Million (2021-2026)
  • Table 319. Cluster Headache Drug Surgery , by Region USD Million (2021-2026)
  • Table 320. Cluster Headache Drug: by Route of Administration(USD Million)
  • Table 321. Cluster Headache Drug Oral , by Region USD Million (2021-2026)
  • Table 322. Cluster Headache Drug Topical , by Region USD Million (2021-2026)
  • Table 323. Cluster Headache Drug Intravenous , by Region USD Million (2021-2026)
  • Table 324. Cluster Headache Drug Others , by Region USD Million (2021-2026)
  • Table 325. Cluster Headache Drug: by Diagnosis(USD Million)
  • Table 326. Cluster Headache Drug Neurological Examination , by Region USD Million (2021-2026)
  • Table 327. Cluster Headache Drug MRI , by Region USD Million (2021-2026)
  • Table 328. Cluster Headache Drug CT Scan , by Region USD Million (2021-2026)
  • Table 329. Cluster Headache Drug: by End User(USD Million)
  • Table 330. Cluster Headache Drug Hospitals , by Region USD Million (2021-2026)
  • Table 331. Cluster Headache Drug Homecare , by Region USD Million (2021-2026)
  • Table 332. Cluster Headache Drug Specialty Clinics , by Region USD Million (2021-2026)
  • Table 333. Cluster Headache Drug Others , by Region USD Million (2021-2026)
  • Table 334. South America Cluster Headache Drug, by Country USD Million (2021-2026)
  • Table 335. South America Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 336. South America Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 337. South America Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 338. South America Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 339. South America Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 340. South America Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 341. South America Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 342. Brazil Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 343. Brazil Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 344. Brazil Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 345. Brazil Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 346. Brazil Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 347. Brazil Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 348. Brazil Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 349. Argentina Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 350. Argentina Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 351. Argentina Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 352. Argentina Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 353. Argentina Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 354. Argentina Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 355. Argentina Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 356. Chile Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 357. Chile Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 358. Chile Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 359. Chile Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 360. Chile Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 361. Chile Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 362. Chile Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 363. Rest of South America Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 364. Rest of South America Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 365. Rest of South America Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 366. Rest of South America Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 367. Rest of South America Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 368. Rest of South America Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 369. Rest of South America Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 370. Asia Pacific Cluster Headache Drug, by Country USD Million (2021-2026)
  • Table 371. Asia Pacific Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 372. Asia Pacific Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 373. Asia Pacific Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 374. Asia Pacific Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 375. Asia Pacific Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 376. Asia Pacific Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 377. Asia Pacific Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 378. China Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 379. China Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 380. China Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 381. China Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 382. China Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 383. China Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 384. China Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 385. Japan Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 386. Japan Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 387. Japan Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 388. Japan Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 389. Japan Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 390. Japan Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 391. Japan Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 392. India Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 393. India Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 394. India Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 395. India Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 396. India Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 397. India Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 398. India Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 399. South Korea Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 400. South Korea Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 401. South Korea Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 402. South Korea Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 403. South Korea Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 404. South Korea Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 405. South Korea Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 406. Singapore Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 407. Singapore Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 408. Singapore Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 409. Singapore Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 410. Singapore Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 411. Singapore Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 412. Singapore Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 413. Malaysia Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 414. Malaysia Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 415. Malaysia Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 416. Malaysia Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 417. Malaysia Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 418. Malaysia Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 419. Malaysia Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 420. Thailand Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 421. Thailand Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 422. Thailand Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 423. Thailand Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 424. Thailand Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 425. Thailand Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 426. Thailand Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 427. Australia Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 428. Australia Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 429. Australia Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 430. Australia Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 431. Australia Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 432. Australia Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 433. Australia Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 434. Rest of Asia-Pacific Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 435. Rest of Asia-Pacific Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 436. Rest of Asia-Pacific Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 437. Rest of Asia-Pacific Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 438. Rest of Asia-Pacific Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 439. Rest of Asia-Pacific Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 440. Rest of Asia-Pacific Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 441. Europe Cluster Headache Drug, by Country USD Million (2021-2026)
  • Table 442. Europe Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 443. Europe Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 444. Europe Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 445. Europe Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 446. Europe Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 447. Europe Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 448. Europe Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 449. Germany Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 450. Germany Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 451. Germany Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 452. Germany Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 453. Germany Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 454. Germany Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 455. Germany Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 456. France Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 457. France Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 458. France Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 459. France Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 460. France Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 461. France Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 462. France Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 463. Italy Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 464. Italy Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 465. Italy Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 466. Italy Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 467. Italy Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 468. Italy Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 469. Italy Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 470. United Kingdom Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 471. United Kingdom Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 472. United Kingdom Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 473. United Kingdom Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 474. United Kingdom Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 475. United Kingdom Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 476. United Kingdom Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 477. Netherlands Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 478. Netherlands Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 479. Netherlands Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 480. Netherlands Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 481. Netherlands Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 482. Netherlands Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 483. Netherlands Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 484. Spain Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 485. Spain Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 486. Spain Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 487. Spain Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 488. Spain Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 489. Spain Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 490. Spain Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 491. Sweden Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 492. Sweden Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 493. Sweden Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 494. Sweden Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 495. Sweden Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 496. Sweden Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 497. Sweden Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 498. Belgium Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 499. Belgium Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 500. Belgium Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 501. Belgium Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 502. Belgium Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 503. Belgium Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 504. Belgium Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 505. Poland Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 506. Poland Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 507. Poland Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 508. Poland Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 509. Poland Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 510. Poland Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 511. Poland Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 512. Norway Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 513. Norway Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 514. Norway Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 515. Norway Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 516. Norway Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 517. Norway Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 518. Norway Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 519. Austria Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 520. Austria Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 521. Austria Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 522. Austria Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 523. Austria Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 524. Austria Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 525. Austria Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 526. Russia Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 527. Russia Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 528. Russia Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 529. Russia Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 530. Russia Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 531. Russia Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 532. Russia Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 533. Rest of Europe Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 534. Rest of Europe Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 535. Rest of Europe Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 536. Rest of Europe Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 537. Rest of Europe Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 538. Rest of Europe Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 539. Rest of Europe Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 540. MEA Cluster Headache Drug, by Country USD Million (2021-2026)
  • Table 541. MEA Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 542. MEA Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 543. MEA Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 544. MEA Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 545. MEA Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 546. MEA Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 547. MEA Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 548. Middle East Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 549. Middle East Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 550. Middle East Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 551. Middle East Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 552. Middle East Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 553. Middle East Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 554. Middle East Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 555. Africa Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 556. Africa Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 557. Africa Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 558. Africa Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 559. Africa Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 560. Africa Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 561. Africa Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 562. North America Cluster Headache Drug, by Country USD Million (2021-2026)
  • Table 563. North America Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 564. North America Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 565. North America Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 566. North America Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 567. North America Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 568. North America Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 569. North America Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 570. United States Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 571. United States Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 572. United States Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 573. United States Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 574. United States Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 575. United States Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 576. United States Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 577. Canada Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 578. Canada Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 579. Canada Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 580. Canada Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 581. Canada Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 582. Canada Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 583. Canada Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 584. Mexico Cluster Headache Drug, by Type USD Million (2021-2026)
  • Table 585. Mexico Cluster Headache Drug, by Drug USD Million (2021-2026)
  • Table 586. Mexico Cluster Headache Drug, by Mechanism of Action USD Million (2021-2026)
  • Table 587. Mexico Cluster Headache Drug, by Treatment USD Million (2021-2026)
  • Table 588. Mexico Cluster Headache Drug, by Route of Administration USD Million (2021-2026)
  • Table 589. Mexico Cluster Headache Drug, by Diagnosis USD Million (2021-2026)
  • Table 590. Mexico Cluster Headache Drug, by End User USD Million (2021-2026)
  • Table 591. Research Programs/Design for This Report
  • Table 592. Key Data Information from Secondary Sources
  • Table 593. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cluster Headache Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Cluster Headache Drug: by Drug USD Million (2015-2020)
  • Figure 6. Global Cluster Headache Drug: by Mechanism of Action USD Million (2015-2020)
  • Figure 7. Global Cluster Headache Drug: by Treatment USD Million (2015-2020)
  • Figure 8. Global Cluster Headache Drug: by Route of Administration USD Million (2015-2020)
  • Figure 9. Global Cluster Headache Drug: by Diagnosis USD Million (2015-2020)
  • Figure 10. Global Cluster Headache Drug: by End User USD Million (2015-2020)
  • Figure 11. South America Cluster Headache Drug Share (%), by Country
  • Figure 12. Asia Pacific Cluster Headache Drug Share (%), by Country
  • Figure 13. Europe Cluster Headache Drug Share (%), by Country
  • Figure 14. MEA Cluster Headache Drug Share (%), by Country
  • Figure 15. North America Cluster Headache Drug Share (%), by Country
  • Figure 16. Global Cluster Headache Drug share by Players 2020 (%)
  • Figure 17. Global Cluster Headache Drug share by Players (Top 3) 2020(%)
  • Figure 18. Global Cluster Headache Drug share by Players (Top 5) 2020(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 22. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 26. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 28. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 32. Sun Pharmaceutical Industries Ltd (India) Revenue, Net Income and Gross profit
  • Figure 33. Sun Pharmaceutical Industries Ltd (India) Revenue: by Geography 2020
  • Figure 34. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2020
  • Figure 36. TrioxBio Inc (Israel) Revenue, Net Income and Gross profit
  • Figure 37. TrioxBio Inc (Israel) Revenue: by Geography 2020
  • Figure 38. Aurobindo Pharma (India) Revenue, Net Income and Gross profit
  • Figure 39. Aurobindo Pharma (India) Revenue: by Geography 2020
  • Figure 40. Endo Pharmaceuticals Inc (Ireland) Revenue, Net Income and Gross profit
  • Figure 41. Endo Pharmaceuticals Inc (Ireland) Revenue: by Geography 2020
  • Figure 42. Chengdu Tiantaishan pharmaceutical Co.,Ltd (China) Revenue, Net Income and Gross profit
  • Figure 43. Chengdu Tiantaishan pharmaceutical Co.,Ltd (China) Revenue: by Geography 2020
  • Figure 44. Global Cluster Headache Drug: by Type USD Million (2021-2026)
  • Figure 45. Global Cluster Headache Drug: by Drug USD Million (2021-2026)
  • Figure 46. Global Cluster Headache Drug: by Mechanism of Action USD Million (2021-2026)
  • Figure 47. Global Cluster Headache Drug: by Treatment USD Million (2021-2026)
  • Figure 48. Global Cluster Headache Drug: by Route of Administration USD Million (2021-2026)
  • Figure 49. Global Cluster Headache Drug: by Diagnosis USD Million (2021-2026)
  • Figure 50. Global Cluster Headache Drug: by End User USD Million (2021-2026)
  • Figure 51. South America Cluster Headache Drug Share (%), by Country
  • Figure 52. Asia Pacific Cluster Headache Drug Share (%), by Country
  • Figure 53. Europe Cluster Headache Drug Share (%), by Country
  • Figure 54. MEA Cluster Headache Drug Share (%), by Country
  • Figure 55. North America Cluster Headache Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Pfizer Inc (United States)
  • AstraZeneca (United Kingdom)
  • Eli Lilly and Company (United States)
  • Sun Pharmaceutical Industries Ltd (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • TrioxBio Inc (Israel)
  • Aurobindo Pharma (India)
  • Endo Pharmaceuticals Inc (Ireland)
  • Chengdu Tiantaishan pharmaceutical Co.,Ltd (China)
Additional players considered in the study are as follows:
WOCKHARDT (India) , Shanghai Soho Yiming Pharmaceutical Co., Ltd (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation